Aktuellt
SENASTE
Redeye updates its estimates following Surgical Science’s Q2 2023 report, which featured a ‘mixed bag’. We judge that notable positives from the report include c30% y/y Industry/OEM sales growth and EBITDA/EBIT aligning with our expectations. Notable negatives include net sales coming in c5% below our expectations due to c8% lower-than-expected Educational Products sales. We finetune our estimates and valuation.
LÄS MER
